CBS62logoNEW2013_blue_final_header_White wwj950-sm2011b 971-ticket-35smb 35h_CBSSportsRad_Detroit

HR Notices From June 14

View Comments
(credit: istock) Technology Report
Read More

George Arida Named to NanoBio Board of Directors: Ann Arbor-based NanoBio Corp. Tuesday announced that George Arida, managing director at Venture Investors LLC, has been appointed to the company’s board of directors. Venture Investors is an investment firm that provides funding to health care and technology companies in the Midwest. Arida has a proven track record of identifying emerging health care companies and guiding growth initiatives, business strategy, and financial decisions to help create exciting exit opportunities. He joined Venture Investors in 2000 and was appointed managing director of Venture Investors Early Stage Fund IV in 2006. Prior to joining Venture Investors, Arida was the CFO of a financial consulting and brokerage firm. Arida served as chairman of the board of directors of Nerites Inc. through the January 2011 acquisition by Kensey Nash and served as chairman of Zystor Therapeutics Inc. He currently serves as chairman of the board of directors of Celleration Inc. He also serves on the board of directors for Chromatin Inc., ProCertus BioPharm Inc., and the Mid-America Healthcare Investors Network. Arida holds a bachelor’s degree in chemical engineering from the University of Illinois at Urbana-Champaign and an MBA with high honors from the University of Chicago. NanoBio is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat technology platform. The company’s lead product candidates are treatments for herpes labialis (licensed to GSK in the U.S. and Canada), onychomycosis, acne, cystic fibrosis and a broad platform of intranasal vaccines.

View Comments
blog comments powered by Disqus
Follow

Get every new post delivered to your Inbox.

Join 1,884 other followers